Sobi and Savient Pharmaceuticals Inc. (SVNT: Quote) announced Tuesday that they have entered into an agreement for the co-promotion of Kineret (anakinra) in the U.S.
Kineret, a recombinant IL-1 receptor antagonist, is a treatment for rheumatoid arthritis or RA and indicated for the reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active RA in patients 18 years of age or older who have failed one or more disease modifying antirheumatic drugs or DMARDs.
Kineret is also indicated in the U.S. for the treatment of children and adults with the severe form of Cryopyrin-Associated Periodic Syndromes or CAPS called Neonatal-Onset Multisystem Inflammatory Disease or NOMID.
Savient is a specialty biopharmaceutical company that has developed and commercialized KRYSTEXXA (pegloticase) for the treatment of refractory chronic gout in the U.S.
As per the terms of the agreement, Sobi has granted to Savient the exclusive right to co-promote the sale of Kineret with Sobi in the U.S. Savient will market and promote Kineret beginning April 1, 2013. Sobi will remain responsible for all Kineret commercial drug manufacturing, supply, safety, and regulatory activities.
Rheumatoid arthritis is a common systemic disease that affects connective tissue. Arthritis is the dominant clinical manifestation, involving many joints, especially those of the hands and feet. The course is variable, but often chronic and progressive, leading to deformity and disability. Patients with rheumatoid arthritis produce excess amounts of inflammatory cytokines, among them Interleukin-1. This leads to harmful effects such as swelling and tissue damage.
| || |
| To receive FREE breaking news email alerts for Savient Pharmaceuticals Inc and others in your portfolio|
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org